164 related articles for article (PubMed ID: 15033141)
1. An overview of parkinsonian syndromes: data from the literature and from an Italian data-base.
Pezzoli G; Canesi M; Galli C
Sleep Med; 2004 Mar; 5(2):181-7. PubMed ID: 15033141
[TBL] [Abstract][Full Text] [Related]
2. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
Goedert M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
[TBL] [Abstract][Full Text] [Related]
3. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs.
Burns JM; Galvin JE; Roe CM; Morris JC; McKeel DW
Neurology; 2005 Apr; 64(8):1397-403. PubMed ID: 15851730
[TBL] [Abstract][Full Text] [Related]
4. NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC).
Yokota O; Terada S; Ishizu H; Tsuchiya K; Kitamura Y; Ikeda K; Uéda K; Kuroda S
Acta Neuropathol; 2002 Oct; 104(4):333-41. PubMed ID: 12200618
[TBL] [Abstract][Full Text] [Related]
5. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
Hauw JJ; Hausser-Hauw C; Duyckaerts C
Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S59-70. PubMed ID: 14646802
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies.
Chalmers KA; Love S
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration.
Josephs KA; Tsuboi Y; Cookson N; Watt H; Dickson DW
Arch Neurol; 2004 Oct; 61(10):1579-84. PubMed ID: 15477512
[TBL] [Abstract][Full Text] [Related]
9. Co-occurrence of Parkinson's disease with progressive supranuclear palsy.
Judkins AR; Forman MS; Uryu K; Hinkle DA; Asbury AK; Lee VM; Trojanowski JQ
Acta Neuropathol; 2002 May; 103(5):526-30. PubMed ID: 11935271
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in the neuropathological diagnosis of Parkinson's disease and parkinsonism.
Michotte A
Acta Neurol Belg; 2003 Sep; 103(3):155-8. PubMed ID: 14626695
[TBL] [Abstract][Full Text] [Related]
11. Lewy bodies in progressive supranuclear palsy.
Mori H; Oda M; Komori T; Arai N; Takanashi M; Mizutani T; Hirai S; Mizuno Y
Acta Neuropathol; 2002 Sep; 104(3):273-8. PubMed ID: 12172913
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of alpha-synuclein pathology in the cerebellum of Guamanian patients with parkinsonism-dementia complex.
Sebeo J; Hof PR; Perl DP
Acta Neuropathol; 2004 Jun; 107(6):497-503. PubMed ID: 15024581
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's syndrome associated with neurofibrillary degeneration and tau pathologic findings.
Lees AJ
Mov Disord; 2003 Sep; 18 Suppl 6():S28-33. PubMed ID: 14502653
[TBL] [Abstract][Full Text] [Related]
14. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.
Greffard S; Verny M; Bonnet AM; Seilhean D; Hauw JJ; Duyckaerts C
Neurobiol Aging; 2010 Jan; 31(1):99-103. PubMed ID: 18457903
[TBL] [Abstract][Full Text] [Related]
15. [Recent neuropathology of parkinsonian syndromes].
Duyckaerts C; Verny M; Hauw JJ
Rev Neurol (Paris); 2003 May; 159(5 Pt 2):3S11-8. PubMed ID: 12773883
[TBL] [Abstract][Full Text] [Related]
16. Lewy bodies in progressive supranuclear palsy represent an independent disease process.
Uchikado H; DelleDonne A; Ahmed Z; Dickson DW
J Neuropathol Exp Neurol; 2006 Apr; 65(4):387-95. PubMed ID: 16691119
[TBL] [Abstract][Full Text] [Related]
17. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions.
Popescu A; Lippa CF; Lee VM; Trojanowski JQ
Arch Neurol; 2004 Dec; 61(12):1915-9. PubMed ID: 15596612
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation.
Spira PJ; Sharpe DM; Halliday G; Cavanagh J; Nicholson GA
Ann Neurol; 2001 Mar; 49(3):313-9. PubMed ID: 11261505
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
20. A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease.
Zarranz JJ; Ferrer I; Lezcano E; Forcadas MI; Eizaguirre B; Atarés B; Puig B; Gómez-Esteban JC; Fernández-Maiztegui C; Rouco I; Pérez-Concha T; Fernández M; Rodríguez O; Rodríguez-Martínez AB; de Pancorbo MM; Pastor P; Pérez-Tur J
Neurology; 2005 May; 64(9):1578-85. PubMed ID: 15883319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
